Gavilast 75mg Tablet

Symptomatic relief of heartburn, indigestion, acid indigestion and hyperacidity. UK/G-OTC/0318/0033e

Available in: 12s

ranitidine 75mg

Do not store above 30°C. Store in original package to protect from light.

Oral administration. One tablet to be swallowed with water, as soon as symptoms arise. If symptoms persist for more than 1 hour or return, take another tablet. No more than 2 tablets in 24 hours. Do not take tablets for more than 6 days without advice of pharmacist or doctor

Treatment with a histamine H2-antagonist such as ranitidine may mask symptoms associated with carcinoma of the stomach and may therefore delay diagnosis of the condition. Ranitidine is excreted via the kidney and so plasma levels of the drug are increased in patients with severe renal impairment. Ranitidine 75 mg film-coated tablet is not suitable for these patients without medical supervision. People taking non-steroidal anti-inflammatory drugs, especially those with a history of peptic ulcer and the elderly should not self-medicate with Ranitidine 75 mg film-coated tablet but seek their doctor's advice before use. People with a history of porphyria should avoid use of the product. Consumers will be advised not to purchase a second pack of tablets without the advice of a pharmacist of doctor. The product is not indicated in the following people without seeking their doctor's advice: • Patients with severe renal and/or hepatic impairment. • Patients under regular medical supervision for other reasons. • Patients taking medications either physician prescribed or self prescribed. • Those with difficulty swallowing, persistent stomach pain or unintended weight loss in association with symptoms of indigestion. • Those who are middle-aged or elderly with new or recently changed symptoms of indigestion. In patients such as the elderly, persons with chronic lung disease, diabetes or the immunocompromised, there may be an increased risk of developing community acquired pneumonia.A large epidemiological study showed an increased risk of developing community acquired pneumonia in current users of H2 receptor antagonists versus those who had stopped treatment, with an observed adjusted relative risk increase of 1.82 (95% CI, 1.26–2.64).